Capecitabine and advanced gastric cancer ... additional dose-finding and comparative efficacy studies are needed to confirm the role of S-1 in the treatment of advanced gastric cancer (AGC).

The maximum tolerated dose (MTD) was defined as ixabepilone 40 mg/m 2 plus capecitabine 2000 mg/m 2 daily for schedule A. Tumor Response (Phase II).